- Home
- WOOF vs EVMN Comparison
WOOF vs EVMN Comparison
Compare WOOF & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOOF | EVMN |
|---|---|---|
| Founded | 1965 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.9M | 892.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | WOOF | EVMN |
|---|---|---|
| Price | $2.36 | $24.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $3.83 | ★ $44.17 |
| AVG Volume (30 Days) | ★ 1.5M | 988.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.26 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $6,116,462,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.64 | N/A |
| P/E Ratio | $59.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.28 | $13.89 |
| 52 Week High | $4.19 | $33.20 |
Technical Indicators
Market Signals| Indicator | WOOF | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.04 | 49.61 |
| Support Level | N/A | $15.25 |
| Resistance Level | $2.60 | $33.20 |
| Average True Range (ATR) | 0.12 | 2.55 |
| MACD | -0.00 | -0.63 |
| Stochastic Oscillator | 24.76 | 27.75 |
Price Performance
Historical ComparisonAbout WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.